Trials / Completed
CompletedNCT03625895
Agrylin Drug Use-Result Survey
Agrylin Capsules 0.5 mg Drug Use-Result Survey
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,826 (actual)
- Sponsor
- Takeda · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The objective of this survey is to collect data to evaluate the safety and efficacy of anagrelide hydrochloride in the post-marketing phase in participants diagnosed with Essential Thrombocythemia (ET).
Detailed description
Anagrelide hydrochloride Drug Use-Result Survey
Conditions
Timeline
- Start date
- 2014-11-25
- Primary completion
- 2021-03-11
- Completion
- 2021-03-11
- First posted
- 2018-08-10
- Last updated
- 2023-02-27
- Results posted
- 2023-02-27
Locations
488 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT03625895. Inclusion in this directory is not an endorsement.